CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies ...
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today ...
Why some heavy drinkers develop advanced liver disease, while others do not
Why do some people who consume a few glasses of alcohol a day develop advanced liver disease while others who drink the same ...
TMCnet7 小时
Galecto to Participate in Upcoming Investor Conferences
A live webcast of the presentation will be available via the Upcoming Events section of the Company’s investor relations website at https://ir.galecto.co/news-and-events/events. An archived replay ...
Business Weekly2 小时
Qureight and Avalyn join forces to combat pulmonary fibrosis
A transatlantic Cambridge2Cambridge alliance between Qureight in the UK and Avalyn Pharma Inc in Massachusetts – is seeking ...
CytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal ...
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...
TipRanks on MSN19 小时
AdAlta Limited Unveils Strategic ‘East to West’ Cellular Immunotherapy Approach
AdAlta Ltd. ( ($AU:1AD) ) just unveiled an announcement. AdAlta Limited is set to host an investor webinar to discuss its ‘East to West’ cellular ...
来自MSN19 小时
New fatty liver disease treatment could save millions of people worldwide
Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...